Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $4.2 million.

  • Zevra Therapeutics' Free Cash Flow rose 12290.39% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.2 million, marking a year-over-year increase of 6520.93%. This contributed to the annual value of -$69.7 million for FY2024, which is 10592.06% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Free Cash Flow stood at $4.2 million, which was up 12290.39% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Free Cash Flow ranged from a high of $16.5 million in Q2 2021 and a low of -$19.1 million during Q2 2024
  • Moreover, its 5-year median value for Free Cash Flow was -$4.5 million (2022), whereas its average is -$6.3 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 65220.76% in 2021, then tumbled by 41976.88% in 2022.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Free Cash Flow stood at -$865000.0 in 2021, then plummeted by 419.77% to -$4.5 million in 2022, then plummeted by 260.99% to -$16.2 million in 2023, then dropped by 0.12% to -$16.2 million in 2024, then skyrocketed by 125.57% to $4.2 million in 2025.
  • Its Free Cash Flow was $4.2 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$8.3 million in Q1 2025.